USPTO serial 99310861
PROVIDUS
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- MARTIN, JENNIFER MCGARRY
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with PROVIDUS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $150
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Courtney Thompson
Courtney Thompson Fredrikson & Byron, P.A.60 South Sixth StreetSuite 1500Minneapolis, MN 55402Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | (based on 1(a)) Scientific and technological services, namely, scientific research, pharmaceutical drug development, and biochemical analysis in the field of drug discovery; medical research and conducting clinical trials for pharmaceutical products; data computer modeling services in the field of pharmaceutical development and medical technology; Scientific services and research namely conducting scientific pharmaceutical product feasibility studies and product designing medical devices and instruments for clinical trials; Scientific services and product design, namely conducting scientific pharmaceutical product feasibility studies and designing medical devices and instruments for clinical trials; Platform as a service (PAAS) comprising software platforms for the transmission of images, audiovisual content, video content and messages; Scientific research for medical purposes; product research services, design and development of instruments for control and diagnostics; Scientific research; Electronic data storage; Technical writing, namely medical writing services for the development of medical protocols, clinical study reports, researcher pamphlets, safety reports, informed consent forms, meeting summaries, posters, manuscripts, study diagrams, manuals, and literature reviews; Design, implementation and management of clinical and observational clinical research study protocols; Electronic storage of files and documents; computer diagnostic services; computer systems analysis services; providing online non-downloadable software featuring clinical study and clinical trial management system tools via a website; providing online non-downloadable software featuring access to study management files; programming of software for study management files and electronic storage services for archiving temporary files throughout the clinical study lifecycle; scientific research, namely programming of software for biostatistics, development of protocols for sample size and statistical power calculations, randomization plans, statistical analysis plans; programming of computer software for validation in a statistical analysis system for others; providing online non-downloadable software enabling interpretation and reporting of data for clinical trial reports and publications; product development for others; scientific research, namely intermediate analysis for early decision making in clinical trials; providing online non-downloadable software for providing access to databases and data lists ready for a New Drug Application (NDA), regulatory submission-compliant data files, study data tabulation and data on model regulatory submission standards; medical research and development for new products for others in the field of medical surveillance and safety plans ongoing oversight of patient-level studies and review of safety data, interpretation of study protocol, consultation on potential safety and medical issues and 24/7 medical surveillance coverage; pharmaceutical drug development services; drug discovery services of adverse events from clinical trials; pharmaceutical drug development services, namely, development of safety update reports and other aggregate reports, development of management safety plans and medical surveillance plans; product quality testing of clinical trial's documentation, for example, standard operating procedures (sops) and work instructions, internal system reviews, site audits, provider evaluations; Medical research in the field of pharmacology namely simulation, dose selection and optimization, biomarker and endpoint selection, study design optimization, population pharmacokinetic and pharmacodynamic modeling, exposure response modeling; Medical research; Information related to scientific and medical research in the area of clinical trials, namely the design of clinical trials and outcome measures for studying human diseases, or studying or testing drugs, devices, or medical treatment methods on humans; scientific research in the nature of conducting clinical trials for third parties studying human diseases, or studying or testing drugs, devices, or medical treatment methods on humans; Custom computer programming in the field of image training and integration into computer systems of suitability data with interactive response technology (IRT); product design and development of computer databases for the collection, storage, management, analysis and validation of data for use in the medical and pharmaceutical fields; electronic data storage services for archiving presentations; Providing information on clinical studies via an interactive website. | ACTIVE | Jun 20, 2025 |
| 044 | (based on 1(b) and 44(e)) Healthcare services, namely, monitoring and follow-up of patients enrolled in non-interventional studies; Providing medical information in the context of real-world evidence (RWE) and post-market studies. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 22, 2026 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Sep 15, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 21, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 21, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 15, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 24, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 23, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 23, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 23, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 24, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 24, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 24, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 3, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 3, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 3, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 19, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 19, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 19, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 15, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 8, 2025 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Dec 8, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 30, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 30, 2025 | NWAP | NEW APPLICATION ENTERED | — |